MYL6P4

Across TCGA pan-cancer cohorts, MYL6P4 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated MYL6P4 data layer.

The strongest signal is observed in uveal melanoma (UVM), where higher MYL6P4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MYL6P4 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

UVM, STAD, and LUAD are the cancer types where MYL6P4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Tertile	All	0.037	0.858	<.001	108	view →
STAD	OS	Median	III,IV	0.321	0.656	.006	74	view →
LUAD	OS	Tertile	II,III,IV	0.422	0.636	.005	43	view →
BRCA	DFS	Tertile	All	0.140	1.000	.001	36	view →
READ	OS	Median	IV	0.443	0.834	.003	24	view →
DLBC	OS	Tertile	III,IV	0.650	1.000	.009	23	view →
KIRP	OS	Quartile	III,IV	0.616	0.871	.004	22	view →
OV	DFS	Median	II,III,IV	0.128	0.187	.018	20	view →
LIHC	OS	Tertile	II,III,IV	0.303	0.661	.020	15	view →
LGG	DFS	Tertile	All	0.219	0.452	.007	9	view →
LUSC	OS	Tertile	II,III,IV	0.425	0.713	.034	9	view →
HNSC	OS	Tertile	IV	0.318	0.557	.028	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

MYL6P4–UVM (OS)

Open the UVM breakdown →